Biocryst Pharmaceuticals (BCRX) Asset Writedowns and Impairment (2023 - 2026)

Biocryst Pharmaceuticals has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $74000.0 in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment fell 64.59% year-over-year to $74000.0; the trailing twelve-month figure through Mar 2026 stood at $850000.0 (down 45.48% YoY), and the FY2025 full-year result was $985000.0, down 27.04% from the prior year.
• Asset Writedowns and Impairment for Q1 2026 stood at $74000.0, up from -$71000.0 in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $1.4 million in Q3 2024, with the low at -$71000.0 in Q4 2025.
• Historically, Asset Writedowns and Impairment has averaged $329750.0 across 4 years, with a median of $52000.0 in 2025.
• The largest YoY upside for Asset Writedowns and Impairment was 81600.0% in 2025 against a maximum downside of 545.45% in 2025.
• Biocryst Pharmaceuticals' Asset Writedowns and Impairment stood at $1.3 million in 2023, then sank by 100.84% to -$11000.0 in 2024, then plunged by 545.45% to -$71000.0 in 2025, then surged by 204.23% to $74000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $74000.0 (Q1 2026), -$71000.0 (Q4 2025), and $30000.0 (Q3 2025), per Business Quant data.